Bristol-Myers Squibb Company
BMYNYSEHealthcare● Active
$56.10
$-1.18(-2.05%)
Market Cap$114.5B
P/E Ratio—
52W High$62.89
52W Low$42.52
Bristol-Myers Squibb Company (BMY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BMY · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$1.58
Est. $1.42 · +11.3%
Revenue
$11.49B
Est. $10.93B · +5.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 10-Quarter EPS Beat Streak
BMY reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Oct 29, 2026 | $1.60 | — | — | — | $12.02B | — |
| ◌ Q3 FY2026 | Jul 30, 2026 | $1.61 | — | — | — | $11.70B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $1.42 | $1.58 | +11.3% | $11.49B | $10.93B | +5.1% |
| ▲ Q1 FY2026 | Feb 5, 2026 | $1.23 | $1.26 | +2.4% | $12.50B | $12.28B | +1.8% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $1.52 | $1.63 | +7.2% | $12.22B | $11.85B | +3.1% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $1.09 | $1.46 | +33.9% | $12.27B | $11.44B | +7.2% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $1.49 | $1.80 | +20.8% | $11.20B | $10.70B | +4.7% |
| ▲ Q1 FY2025 | Feb 6, 2025 | $1.47 | $1.67 | +13.6% | $12.34B | $11.57B | +6.7% |
Q4 FY2026
Oct 29, 2026
EPS Actual
—
EPS Est.
$1.60
EPS Surpr.
—
Revenue
—
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$1.61
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$1.58
EPS Est.
$1.42
EPS Surpr.
+11.3%
Revenue
$11.49B
Q1 FY2026
Feb 5, 2026Beat
EPS Actual
$1.26
EPS Est.
$1.23
EPS Surpr.
+2.4%
Revenue
$12.50B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$1.63
EPS Est.
$1.52
EPS Surpr.
+7.2%
Revenue
$12.22B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$1.46
EPS Est.
$1.09
EPS Surpr.
+33.9%
Revenue
$12.27B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$1.80
EPS Est.
$1.49
EPS Surpr.
+20.8%
Revenue
$11.20B
Q1 FY2025
Feb 6, 2025Beat
EPS Actual
$1.67
EPS Est.
$1.47
EPS Surpr.
+13.6%
Revenue
$12.34B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.29 | $1.32 | $1.36 | 7 |
| Q3 FY2028 | $1.23 | $1.26 | $1.30 | 7 |
| Q2 FY2028 | $1.28 | $1.31 | $1.35 | 7 |
| Q1 FY2028 | $1.18 | $1.21 | $1.25 | 7 |
| Q4 FY2027 | $1.51 | $1.55 | $1.60 | 6 |
| Q3 FY2027 | $1.50 | $1.53 | $1.58 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $10.0B | $10.2B | $10.4B | 8 |
| Q3 FY2028 | $9.7B | $9.9B | $10.2B | 6 |
| Q2 FY2028 | $10.0B | $10.2B | $10.4B | 5 |
| Q1 FY2028 | $9.8B | $9.9B | $10.2B | 5 |
| Q4 FY2027 | $11.8B | $12.1B | $12.4B | 6 |
| Q3 FY2027 | $11.4B | $11.6B | $11.9B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +11.3% | $57.59 | $60.59 | +5.21% |
| ▲ Q1 FY2026 | Feb 5, 2026 | +2.4% | $57.62 | $59.52 | +3.30% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +7.2% | $42.60 | $45.62 | +7.09% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +33.9% | $45.98 | $43.31 | -5.81% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +20.8% | $48.52 | $48.69 | +0.35% |
| ▲ Q1 FY2025 | Feb 6, 2025 | +13.6% | $59.71 | $57.42 | -3.84% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +20.8% | $52.66 | $55.77 | +5.91% |
| ▲ Q3 FY2024 | Jul 26, 2024 | +27.8% | $45.27 | $50.45 | +11.44% |
Q2 FY2026+5.21%
Report Date
Apr 30, 2026
EPS Beat/Miss
+11.3%
Price Before
$57.59
Price After
$60.59
Q1 FY2026+3.30%
Report Date
Feb 5, 2026
EPS Beat/Miss
+2.4%
Price Before
$57.62
Price After
$59.52
Q4 FY2025+7.09%
Report Date
Oct 30, 2025
EPS Beat/Miss
+7.2%
Price Before
$42.60
Price After
$45.62
Q3 FY2025-5.81%
Report Date
Jul 31, 2025
EPS Beat/Miss
+33.9%
Price Before
$45.98
Price After
$43.31
Q2 FY2025+0.35%
Report Date
Apr 24, 2025
EPS Beat/Miss
+20.8%
Price Before
$48.52
Price After
$48.69
Q1 FY2025-3.84%
Report Date
Feb 6, 2025
EPS Beat/Miss
+13.6%
Price Before
$59.71
Price After
$57.42
Q4 FY2024+5.91%
Report Date
Oct 31, 2024
EPS Beat/Miss
+20.8%
Price Before
$52.66
Price After
$55.77
Q3 FY2024+11.44%
Report Date
Jul 26, 2024
EPS Beat/Miss
+27.8%
Price Before
$45.27
Price After
$50.45
Avg Beat Reaction+2.96%
Beat Rate8 / 8 quarters
Largest Move+11.44% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BMY ends December
Bristol-Myers Squibb Company (BMY) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $1.58 — beating the analyst consensus of $1.42 by +11.3%. BMY has beaten EPS estimates for 10 consecutive quarters. The next BMY earnings date is expected around September 1, 2026.
Each quarter, investors track BMY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BMY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BMY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BMY earnings · 5 questionsBristol-Myers Squibb Company's next earnings report is expected around September 1, 2026. BMY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BMY historically reports after market close (AMC).
BMY earnings datewhen is BMY earningsBMY next earnings datewhen does BMY report earningsBMY earnings calendar
▸ Source: FMP · Bristol-Myers Squibb Company SEC filings · US GAAP · Bristol-Myers Squibb Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026